Celltrion (A068270) Stock Overview
A biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A068270 from our risk checks.
A068270 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Celltrion, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩199,100.00 |
| 52 Week High | ₩251,000.00 |
| 52 Week Low | ₩144,615.38 |
| Beta | 0.40 |
| 1 Month Change | -3.11% |
| 3 Month Change | -5.86% |
| 1 Year Change | 29.58% |
| 3 Year Change | 27.14% |
| 5 Year Change | -23.12% |
| Change since IPO | 2,087.82% |
Recent News & Updates
Recent updates
Here's Why Celltrion (KRX:068270) Can Manage Its Debt Responsibly
Feb 14
Investors Appear Satisfied With Celltrion, Inc.'s (KRX:068270) Prospects
Jan 23Celltrion (KRX:068270) Has A Pretty Healthy Balance Sheet
Nov 03Investors Interested In Celltrion, Inc.'s (KRX:068270) Earnings
Sep 30Celltrion (KRX:068270) Takes On Some Risk With Its Use Of Debt
May 03Shareholder Returns
| A068270 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 2.8% | 2.5% | 6.3% |
| 1Y | 29.6% | 30.6% | 125.8% |
Return vs Industry: A068270 underperformed the KR Biotechs industry which returned 30.6% over the past year.
Return vs Market: A068270 underperformed the KR Market which returned 125.8% over the past year.
Price Volatility
| A068270 volatility | |
|---|---|
| A068270 Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in KR Market | 16.2% |
| 10% least volatile stocks in KR Market | 4.6% |
Stable Share Price: A068270 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A068270's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Hyong-Gi Kim | www.celltrion.com |
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin’s lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. The company is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy.
Celltrion, Inc. Fundamentals Summary
| A068270 fundamental statistics | |
|---|---|
| Market cap | ₩40.91t |
| Earnings (TTM) | ₩1.03t |
| Revenue (TTM) | ₩4.16t |
Is A068270 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A068270 income statement (TTM) | |
|---|---|
| Revenue | ₩4.16t |
| Cost of Revenue | ₩1.70t |
| Gross Profit | ₩2.47t |
| Other Expenses | ₩1.44t |
| Earnings | ₩1.03t |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.91k |
| Gross Margin | 59.27% |
| Net Profit Margin | 24.74% |
| Debt/Equity Ratio | 21.3% |
How did A068270 perform over the long term?
See historical performance and comparisonDividends
Does A068270 pay a reliable dividends?
See A068270 dividend history and benchmarks| Celltrion dividend dates | |
|---|---|
| Ex Dividend Date | Dec 29 2025 |
| Dividend Pay Date | Apr 22 2026 |
| Days until Ex dividend | 107 days |
| Days until Dividend pay date | 7 days |
Does A068270 pay a reliable dividends?
See A068270 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/14 15:37 |
| End of Day Share Price | 2026/04/14 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Celltrion, Inc. is covered by 39 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Girish Bakhru | BofA Global Research |
| Dae Woong Yoo | Bookook Securities Co. Ltd |
| Hyeryeong Kim | CGS International |